Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland

Moleculin Biotech, Inc., a clinical stage pharmaceutical company focused on the development of oncology drug candidates based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced it has begun in Poland recruiting patients in the Company’s second clinical trial to study Annamycin for the treatment of relapsed and refractory adults with acute myeloid leukemia (“AML”).